Breast Cancer

Combined treatment with capivasertib plus fulvestrant yielded a 5.5-month median progression-free survival for patients with HR+ advanced breast cancer.

Patients with early-stage HER2-positive breast cancer experienced a high rate of pathologic complete response with combined preoperative treatment with atezolizumab, epirubicin, trastuzumab, and pertuzumab.

Research published in JAMA Oncology suggest that acute radiation dermatitis may be the result of a common skin bacterium and prevented with a low-cost topical treatment.

A subgroup analysis showed that patients with hormone receptor–positive, HER2-negative advanced breast cancer who had de novo metastatic disease or late recurrence from neoadjuvant therapy achieved better outcomes with ribociclib plus letrozole.

A post-hoc analysis suggests that olaparib may extend progression-free survival in patients with germline BRCA-mutated, HER2-negative metastatic breast cancer, no matter their estrogen receptor expression level.

Trastuzumab deruxtecan outperformed investigators choice of therapy, in terms of safety, among patients with HER2-Low Metastatic Breast Cancer.

Using established guidelines to monitor and intervene early for diarrhea and neutropenia may result in longer treatment durations and sustained benefit from sacituzumab govitecan.

The time to definitive deterioration was delayed among patients receiving trastuzumab deruxtecan vs treatment of physician’s choice in all prespecified scales in DESTINY-Breast02.

Patient-reported outcomes demonstrated a manageable safety profile with abemaciclib.

Patient-reported outcomes among patients who received elacestrant were consistent with other endocrine therapies.

The US Preventive Services Task Force is working on a draft recommendation which would lower the age of breast cancer screenings from 50 years to 40 years for women at average risk.

Extending anastrozole treatment to 10 years in postmenopausal women with hormone receptor–positive breast cancer who have no evidence of disease after 5 years of standard-of-care treatments.

Single-agent adagrasib demonstrated a manageable safety profile and meaningful clinical activity in patients with KRAS G12C–mutated solid tumors.

Rita Deimler, MSN, ANP-BC, outlines best cardiac event monitoring and management practices for patients receiving the CDK4/6 inhibitor ribociclib.

Applying the local anesthetic lidocaine preceding surgery yielded significant survival benefits for patients with early-stage breast cancer.

The FDA has accepted a biologics license application for a proposed trastuzumab biosimilar. The therapy is being considered as adjuvant therapy for certain HER2-overexpressing cancers.

Precision medicine is a term that has been in our oncology language for years, but changes are occurring quickly. As oncology nurses, we need to learn about genomics and biomarkers and what precision medicine means for patients’ outcomes.

Kristin Daly, MSN, ANP-BC, AOCNP, discusses pathogenic variant testing and what it means for oncology nurses.

Isabel Octaviano, RN, details her role and experiences supporting patients during clinical trials.

La-Urshular Brock, MSN, FNP-BC, CNM, discusses how a better understanding of HER2-low status may necessitate more testing for certain patients with breast cancer.

Patritumab deruxtecan generated activity in patients with metastatic or unresectable EGFR-mutated non–small cell lung cancer and HER3-expressing breast cancer.

Patricia Jakel, RN, MN, AOCN discusses adverse event management in the age of new breast cancer treatments.

Lasofoxifene may be helpful in managing vaginal/vulvar symptoms in women with estrogen receptor–positive/HER2-negative breast cancer harboring an ESR1 mutation.

Data from a retrospective analysis confirm the benefit of palbociclib plus an aromatase inhibitor in elderly patients with hormone receptor–positive, HER2-negative advanced/metastatic breast cancer.

Abemaciclib, in combination with endocrine therapy, had been approved as an adjuvant treatment for patients with high-risk, hormone receptor–positive, HER2-negative, node-positive, early breast cancer.

Sarah Donahue, MPH, AOCNP, cochair of the 40th Annual Miami Breast Cancer Conference nursing track, discusses the biggest updates in breast cancer from 2022.

Long-term data support a de-escalated dose of tamoxifen for certain women with breast intraepithelial neoplasia who are unable to receive the standard dose.

Triple-negative breast cancer often occurs in women younger than 40.

Oncology nurses provide perspective on the changing standards of care for patients with triple-negative breast cancer.

The National Comprehensive Cancer Network has updated their guidelines to include neratinib for patients with HER2-negative metastatic breast cancer.